RT Journal Article
T1 Biomarkers of immediate drug hypersensitivity
A1 Mayorga Mayorga, Cristobalina
A1 Ariza, Adriana
A1 Muñoz-Cano, Rosa
A1 Sabato, Vito
A1 Doña, Inmaculada
A1 Torres-Jaén, María Josefa
K1 Biomedicina - Investigación
AB Immediate drug hypersensitivity reactions (IDHRs) are a burden for patients and the health systems. This problem increases when taking into account that only a small proportion of patients initially labelled as allergic are finally confirmed after an allergological workup. The diverse nature of drugs involved will imply different interactions with the immunological system. Therefore, IDHRs can be produced by a wide array of mechanisms mediated by the drug interaction with specific antibodies or directly on effector target cells. These heterogeneous mechanisms imply an enhanced complexity for an accurate diagnosis and the identification of the phenotype and endotype at early stages of the reaction is of vital importance. Currently, several endophenotypic categories (type I IgE/non-IgE, cytokine release, Mast-related G-protein coupled receptor X2 (MRGPRX2) or Cyclooxygenase-1 (COX-1) inhibition and their associated biomarkers have been proposed. A precise knowledge of endotypes will permit to discriminate patients within the same phenotype, which is crucial in order to personalise diagnosis, future treatment and prevention to improve the patient's quality of life.
PB Wiley
YR 2023
FD 2023-11-10
LK https://hdl.handle.net/10630/28915
UL https://hdl.handle.net/10630/28915
LA eng
NO Mayorga C, Ariza A, Muñoz-Cano R, Sabato V, Doña I, Torres MJ. Biomarkers of immediate drug hypersensitivity. Allergy. 2023;00:1-12. doi:10.1111/ all.15933
NO Funding for open Access charge: Universidad de Málaga / CBUA.This work has been supported by the Institute of Health ‘Carlos III’ (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (grants cofunded by European Regional Development). Fund: PI20/01734; PI22/01119; REI-RICORS RD21/0002/0008, RD21/0002/0058. Andalusian Regional Ministry of Health (grant nos. PI-0076-2019, PI-0127-2020, PI-0129-2021, PI21/00329). DrNanoDall project by ISCIII thorough AES 2019 within the ERANET-EuroNanoMed-III framework (AC19/00082). CM holds a ‘Nicolas Monardes’ research contract with the Andalusian Regional Ministry of Health (RC-0004-2021). AA holds a Senior Postdoctoral Contract (RH-0099-2020) with the Andalusian Regional Ministry of Health (cofunded by European Social Fund (ESF): ‘Andalucía se mueve con Europa’). VS is a Senior Clinical Investigator of the Flemish Research Council (FWO; grant 1804523N).
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026